About VGXI
VGXI is a Healthcare company based in The Woodlands (United States) founded in 1997. Contract developer and manufacturer of plasmids. Its chief executive, as recorded, is Young K Park. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Diversified. Its competitors include Metabolon, Maze Therapeutics and Seer; 3 of its 3 listed competitors have raised funding.
Company details
VGXI was established in 1997 as a contract manufacturing organization in the biotechnology sector, based in The Woodlands, United States. Services encompass cGMP plasmid DNA production for clinical and commercial applications, highly documented plasmids for viral and toxicological studies, and high-purity preparations for preclinical research. As a subsidiary of GeneOne Life Science, operations support DNA vaccine and gene therapy development.
- Investors
Funding Insights of VGXI
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of VGXI with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in VGXI
VGXI has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include CEPI.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investments are targeted by this private equity firm. | 2017 | cepi.net | Oslo, Norway |
Investor details for VGXI
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of VGXI
18 people are tracked at VGXI (6 in leadership, 12 in team).
| Name | Role | Group |
|---|---|---|
Young K Park | CEO | Leadership |
Jeff Whitmore | Chief Commercial Officer | Leadership |
Christy Franco | Senior Director Of Commercial Operations | Leadership |
Brenda Reichert | Senior Director, HR | Leadership |
Jim Smith | Chief Accounting Officer | Leadership |
Stephen Rodriguez | Director, Process Development | Leadership |
Alyssa Osborne | Process Development Technician | Team |
Sonia P. | Human Resources Assistant | Team |
Jill Beilowitz | Process Development Supervisor | Team |
Bryan Spruell | Upstream Plasmid Manufacturing Technician | Team |
Palas Chanda | Senior Manager | Team |
Jonathan Geisler | Upstream Process Technician IV | Team |
Rebecca Bronikowski | Marketing Operations Specialist | Team |
Thomas Pockevich Jr | Process Development Technician III | Team |
Heather Davidson | Senior Manager, Program Management | Team |
Javier Lopez | Bioprocessing Lead | Team |
Brandon Blair | Process Technician | Team |
John Liu | Senior Process Development Scientist | Team |
Complete people profiles for VGXI
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of VGXI
2 dated milestones of VGXI across 23 years, from founding to its latest funding, stage changes and deals.
- Founded VGXI is founded.
- Funding First funding round.
Competitors of VGXI
VGXI has 3 listed competitors in our database, 3 of them funded. They include Metabolon, Maze Therapeutics and Seer.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| metabolon.com | 2000 | Morrisville, United States | $165.87M | 189 | Solutions for biomarker discovery and diagnostic testing are provided. | |
| mazetx.com | 2018 | Redwood, United States | $496M | 111 | Genetic biomarkers are developed for neurological, metabolic, and renal diseases. | |
| seer.bio | 2017 | San Francisco, United States | $127.5M | 89 | Proteomics platform developed for early cancer and neurological disease detection. |
Detailed competitors of VGXI
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of VGXI
The website of VGXI (vgxii.com) receives about 2.9K visits a month and ranks #6,447,856 among all websites worldwide, #6,583 in Biotechnology and Pharmaceuticals.
- Monthly visits2.9K
▲ 14.2% vs previous month
- Global rank#6,447,856
among all websites
- Category rank#6,583
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.8
- Average visit33 sec
- DevicesDesktop 36% · Mobile 64%
Websites whose visitors overlap most with VGXI. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| fujifilmdiosynth.com | 100% | View details | |||
ambis.co.jp | ambis.co.jp | 99% | #4,543,397 | – | |
| syncobiopartners.com | 99% | View details | |||
| origen.com | 90% | #2,780,725 | View details | ||
seedbiotech.com | seedbiotech.com | 39% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for VGXI
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as VGXI (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vgxi
Complete news archive for VGXI
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VGXI
VGXI was founded in 1997 and raised its 1st funding round 23 years after it was founded.
VGXI is headquartered in The Woodlands, United States. It is registered at The Woodlands, Texas, United States.
Young K Park is the CEO of VGXI, as recorded in our data.
VGXI was established in 1997 as a contract manufacturing organization in the biotechnology sector, based in The Woodlands, United States. Services encompass cGMP plasmid DNA production for clinical and commercial applications, highly documented plasmids for viral and toxicological studies, and high-purity preparations for preclinical research. As a subsidiary of GeneOne Life Science, operations support DNA vaccine and gene therapy development.
VGXI's top competitors include Maze Therapeutics, Metabolon and Seer.
VGXI has 1 investor. Key investors include CEPI.